European Union - English - EMA (European Medicines Agency)

elanco gmbh - pegbovigrastim - colony stimulating factors, immunostimulants, antineoplastic agents - cattle (cows and heifers); cattle - as an aid in a herd management programme, to reduce the risk of clinical mastitis in periparturient dairy cows and heifers during the 30 days following calving.

United States - English - NLM (National Library of Medicine)

elanco animal health - pegbovigrastim (unii: 87m3b1263r) (pegbovigrastim - unii:87m3b1263r) - for the reduction in the incidence of clinical mastitis in the first 30 days of lactation in periparturient dairy cows and periparturient replacement dairy heifers.

New Zealand - English - Ministry for Primary Industries

elanco australasia pty ltd - pegbovigrastim - pegbovigrastim 5.5 g/litre - immune stimulant

Canada - English - Health Canada

elanco canada limited - pegbovigrastim - solution - 15mg - pegbovigrastim 15mg - cattle; cattle

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

elanco animal health (pty) ltd - injection - see ingredients - each 2. ml solution contains pegbovigrastim 15.0 mg pegbovigrastim 15.0 mg - c 21. immune modulating agents c 21. immune modulating agents

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lipegfilgrastim, quantity: 6 mg - injection, solution - excipient ingredients: acetic acid; polysorbate 20; sorbitol; sodium hydroxide; water for injections - lonquex? is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)

Israel - English - Ministry of Health

kamada ltd, israel - pegfilgrastim - solution for injection - pegfilgrastim 10 mg/ml - pegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy, given at intervals of 14 days or more, for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes).

European Union - English - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - pegfilgrastim, quantity: 6 mg - injection, solution - excipient ingredients: sodium; polysorbate 20; acetate; sorbitol; water for injections - for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infection, as manifested by febrile neutropenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - pegfilgrastim, quantity: 6 mg - injection, solution - excipient ingredients: sodium; polysorbate 20; acetate; sorbitol; water for injections - for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infection, as manifested by febrile neutropenia.